Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Athena Gold Closes Private Placement
Expert: African Lithium Key to China’s Battery Supply...
David Erfle: Silver Staging “Powerful” Breakout; Plus Gold...
C29 Metals shifts focus to Mayfield Copper Project
Blackstone Secures $22.6m for Mankayan Copper-Gold Drilling
QEM Appoints Robert Cooper as Director, following Leadership...
DFS Investor Webinar Presentation
Lithium Universe LtdPV SOLAR CELL Recycling Acquisition Legal...
Acquisition Legal DD Complete
Google makes first foray into fusion in venture...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

by admin September 23, 2024
September 23, 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved the required response rate to support continued enrolment in the study. Six (6) patients have now recorded confirmed partial responses (PRs) out of 16 assessed at the four-month timepoint, indicating that the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is sufficiently active to support continuation of the trial.

HIGHLIGHTS

Six (6) patients in the Company’s ACCENT trial in pancreatic cancer have now achieved the required reduction in tumour size with no detection of new lesionsThe ACCENT trial can now proceed to recruit the next cohort of 24 patients, giving a total of 50 patients on studyThe ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients

The formal term ‘confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period.

A total of 50 patients are planned for the Phase 2a ACCENT trial. With the six (6) confirmed PRs now obtained, recruitment of the remaining 24 patients in the trial will begin at the existing open trial sites in Australia and South Korea. Recruitment of the second cohort of patients is expected to be completed by end of Q1 2025.

A detailed interim analysis of the Phase 2a trial data obtained to date will be reported in the coming weeks; however, key points are noted below:

Narmafotinib continues to be generally well tolerated by patients with no safety trends identified or dose reductions recorded to dateIn addition to 6 confirmed PRs, there have been 7 patients who have recorded stable disease over 2 or more months, including one patient whose stable disease has improved to achieve a partial response at their 4-month assessment

Amplia CEO and MD Dr Chris Burns commented: “Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial’

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Operations Update
next post
Nordic Nickel Limited (ASX: NNL) – Trading Halt

You may also like

Element79 Provides Updates on ASM Formalization and Progress...

January 1, 2025

Revision to Updated Scoping Study Nueva Sabana Mine,...

December 11, 2024

$4.5M Government Grant Secures Construction Start for Collie...

November 12, 2024

Successful completion of Lac Carheil drilling program

April 10, 2025

Allied Critical Metals Commences 5,000 Metre Drill Program...

June 3, 2025

Empire Metals Limited Announces Major Drilling Campaign Targeting...

June 3, 2025

Port of Montreal Strike Exacerbating Canadian Mining Sector’s...

October 2, 2024

Juggernaut Exploration

June 14, 2025

Silver47 Closes First Tranche of Non-brokered Private Placement

March 6, 2025

What is the Gold Spot Price? (Updated 2024)

September 11, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Athena Gold Closes Private Placement

      July 2, 2025
    • Expert: African Lithium Key to China’s Battery Supply Chain Dominance

      July 2, 2025
    • David Erfle: Silver Staging “Powerful” Breakout; Plus Gold Stocks and Copper Squeeze

      July 2, 2025
    • C29 Metals shifts focus to Mayfield Copper Project

      July 2, 2025
    • Blackstone Secures $22.6m for Mankayan Copper-Gold Drilling

      July 2, 2025
    Promotion Image

    banner ads

    Categories

    • Business (751)
    • Economy (829)
    • Investing (2,322)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved